Literature DB >> 15184422

Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools.

S-M Kulmala1, S Syrjänen, I Shabalova, N Petrovichev, V Kozachenko, J Podistov, O Ivanchenko, S Zakharenko, R Nerovjna, L Kljukina, M Branovskaja, V Grunberga, A Juschenko, P Tosi, R Santopietro, K Syrjänen.   

Abstract

The recognition of high-risk human papillomaviruses (HPVs) as etiological agents of cervical cancer has increased the demands to use testing for HPV for the detection of abnormal cervical smears and for cervical cancer screening. The present study compared the performance of the Hybrid Capture 2 (HC2) assay with that of PCR for the detection of significant cervical lesions in 1,511 women with different risks for HPV infections in three New Independent States of the former Soviet Union. The results showed that the level of agreement between the HC2 assay and PCR was substantial, with a kappa (Cohen) value of 0.669 (95% confidence interval [CI], 0.629 to 0.709). Of the 228 samples with discrepant results, 92 were positive by the HC2 assay but negative by PCR, whereas 136 samples were PCR positive but HC2 assay negative. The positive predictive values (PPVs) of the HC2 assay and PCR in detecting high-grade intraepithelial lesions (HSILs) were 4.5% (95% CI, 3.5 to 5.5%) and 3.6% (95% CI, 2.7 to 4.5%), respectively, and the negative predictive values (NPVs) were 99.6% (95% CI, 99.3 to 99.9%) and 99.3% (95% CI, 98.9 to 99.7%), respectively. The sensitivities of the HC2 assay and PCR for the detection of HSILs were 85.2 and 74.0%, respectively, and the specificities were 67.2 and 64.1%, respectively. In receiver operating characteristic (ROC) analysis, the performance of the HC2 assay for the detection of HSILs was excellent (P = 0.0001); the area under the ROC analysis curve was 0.858 (95% CI, 0.811 to 0.905), and the optimal balance between sensitivity (86.5%) and specificity (80%) was obtained with an HC2 assay cutoff level of 15.6 relative light units/positive control. Use of this cutoff would increase the specificity of the HC2 assay to 80.0% without compromising sensitivity. In conclusion, the results of PCR and the HC2 assay were concordant for 85% of samples, resulting in substantial reproducibility. Both tests had low PPVs, equal specificities, and equal (almost 100%) NPVs for the detection of HSILs; but the sensitivity of the HC2 assay was slightly better.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184422      PMCID: PMC427873          DOI: 10.1128/JCM.42.6.2470-2475.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

1.  Evaluation of HPV testing by Hybrid Capture II for routine gynecologic screening.

Authors:  P Schneede; P Hillemanns; F Ziller; A Hofstetter; E Stockfleth; R Arndt; T Meyer
Journal:  Acta Obstet Gynecol Scand       Date:  2001-08       Impact factor: 3.636

2.  HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica.

Authors:  M Schiffman; R Herrero; A Hildesheim; M E Sherman; M Bratti; S Wacholder; M Alfaro; M Hutchinson; J Morales; M D Greenberg; A T Lorincz
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

3.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

4.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

5.  Meta-analysis of Pap test accuracy.

Authors:  M T Fahey; L Irwig; P Macaskill
Journal:  Am J Epidemiol       Date:  1995-04-01       Impact factor: 4.897

6.  Human papillomavirus DNA testing for cervical cancer screening in low-resource settings.

Authors:  L Kuhn; L Denny; A Pollack; A Lorincz; R M Richart; T C Wright
Journal:  J Natl Cancer Inst       Date:  2000-05-17       Impact factor: 13.506

7.  Human papillomavirus DNA is found in the vas deferens.

Authors:  Marjut A M Rintala; Pasi P Pöllänen; Vesa P Nikkanen; Seija E Grénman; Stina M Syrjänen
Journal:  J Infect Dis       Date:  2002-05-17       Impact factor: 5.226

8.  Human papillomavirus infection is transient in young women: a population-based cohort study.

Authors:  M Evander; K Edlund; A Gustafsson; M Jonsson; R Karlsson; E Rylander; G Wadell
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

9.  Acquisition of high-risk human papillomavirus infections and pap smear abnormalities among women in the New Independent States of the Former Soviet Union.

Authors:  Stina Syrjänen; Irena Shabalova; Nicolay Petrovichev; Vladimir Kozachenko; Tatjana Zakharova; Julia Pajanidi; Jurij Podistov; Galina Chemeris; Larisa Sozaeva; Elena Lipova; Irena Tsidaeva; Olga Ivanchenko; Alla Pshepurko; Sergej Zakharenko; Raisa Nerovjna; Ludmila Kljukina; Oksana Erokhina; Marina Branovskaja; Maritta Nikitina; Valerija Grunberga; Alexandr Grunberg; Anna Juschenko; Piero Tosi; Marcella Cintorino; Rosa Santopietro; Kari Syrjänen
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

10.  A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.

Authors:  L A Koutsky; K K Holmes; C W Critchlow; C E Stevens; J Paavonen; A M Beckmann; T A DeRouen; D A Galloway; D Vernon; N B Kiviat
Journal:  N Engl J Med       Date:  1992-10-29       Impact factor: 91.245

View more
  24 in total

1.  Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.

Authors:  Maria T Sandri; Paola Lentati; Elvira Benini; Patrizia Dell'Orto; Laura Zorzino; Francesca M Carozzi; Patrick Maisonneuve; Rita Passerini; Michela Salvatici; Chiara Casadio; Sara Boveri; Mario Sideri
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program.

Authors:  A T Hesselink; N W J Bulkmans; J Berkhof; A T Lorincz; C J L M Meijer; P J F Snijders
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

3.  Optimal positive cutoff points for careHPV testing of clinician- and self-collected specimens in primary cervical cancer screening: an analysis from rural China.

Authors:  Le-Ni Kang; Jose Jeronimo; You-Lin Qiao; Fang-Hui Zhao; Wen Chen; Melissa Valdez; Xun Zhang; Pooja Bansil; Proma Paul; Ping Bai; Roger Peck; Jing Li; Feng Chen; Mark H Stoler; Philip E Castle
Journal:  J Clin Microbiol       Date:  2014-03-26       Impact factor: 5.948

4.  Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance.

Authors:  Philippe Halfon; Elisabeth Trepo; Gilles Antoniotti; Catherine Bernot; Philippe Cart-Lamy; Hacène Khiri; Didier Thibaud; Jean Marron; Agnès Martineau; Guillaume Pénaranda; Dominique Benmoura; Bernard Blanc
Journal:  J Clin Microbiol       Date:  2006-11-22       Impact factor: 5.948

5.  The relationship between hormonal contraception and cervical dysplasia/cancer controlling for human papillomavirus infection: A systematic review.

Authors:  Elle Anastasiou; Katharine J McCarthy; Erica L Gollub; Lauren Ralph; Janneke H H M van de Wijgert; Heidi E Jones
Journal:  Contraception       Date:  2021-11-06       Impact factor: 3.375

6.  Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial.

Authors:  A Sargent; A Bailey; A Turner; M Almonte; C Gilham; H Baysson; J Peto; C Roberts; C Thomson; M Desai; J Mather; H Kitchener
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

7.  Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women.

Authors:  Sotirios Tsiodras; John Georgoulakis; Aikaterini Chranioti; Zanis Voulgaris; Amanda Psyrri; Angeliki Tsivilika; John Panayiotides; Petros Karakitsos
Journal:  BMC Cancer       Date:  2010-02-22       Impact factor: 4.430

8.  Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test.

Authors:  D C Rijkaart; V M H Coupe; F J van Kemenade; D A M Heideman; A T Hesselink; W Verweij; L Rozendaal; R H Verheijen; P J Snijders; J Berkhof; C J L M Meijer
Journal:  Br J Cancer       Date:  2010-08-31       Impact factor: 7.640

9.  The PapilloCheck Assay for Detection of High-Grade Cervical Intraepithelial Neoplasia.

Authors:  Emma J Crosbie; Andrew Bailey; Alex Sargent; Clare Gilham; Julian Peto; Henry C Kitchener
Journal:  J Clin Microbiol       Date:  2015-09-02       Impact factor: 5.948

Review 10.  Comparison of the accuracy of Hybrid Capture II and polymerase chain reaction in detecting clinically important cervical dysplasia: a systematic review and meta-analysis.

Authors:  Hung N Luu; Kristina R Dahlstrom; Patricia Dolan Mullen; Helena M VonVille; Michael E Scheurer
Journal:  Cancer Med       Date:  2013-04-21       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.